MX2011010061A - Biomarcador para monitorear pacientes. - Google Patents

Biomarcador para monitorear pacientes.

Info

Publication number
MX2011010061A
MX2011010061A MX2011010061A MX2011010061A MX2011010061A MX 2011010061 A MX2011010061 A MX 2011010061A MX 2011010061 A MX2011010061 A MX 2011010061A MX 2011010061 A MX2011010061 A MX 2011010061A MX 2011010061 A MX2011010061 A MX 2011010061A
Authority
MX
Mexico
Prior art keywords
biomarker
immunotherapy
monitoring patients
methods
field
Prior art date
Application number
MX2011010061A
Other languages
English (en)
Inventor
Bruce Acres
Berangere Marie-Bastien
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of MX2011010061A publication Critical patent/MX2011010061A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Abstract

La presente invención está en el campo de la inmunoterapia y se refiere a métodos para determinar la eficacia de ciertos tratamientos de inmunoterapia. Los métodos de la invención incluyen medir un biomarcador especial en algún momento después de la iniciación del tratamiento de inmunoterapia para evaluar el resultado clínico del citado tratamiento. La invención tiene por consiguiente aplicaciones al campo de la medicina.
MX2011010061A 2009-03-24 2010-03-23 Biomarcador para monitorear pacientes. MX2011010061A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305256 2009-03-24
PCT/EP2010/053755 WO2010108908A1 (en) 2009-03-24 2010-03-23 Biomarker for monitoring patients

Publications (1)

Publication Number Publication Date
MX2011010061A true MX2011010061A (es) 2011-11-18

Family

ID=42153802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010061A MX2011010061A (es) 2009-03-24 2010-03-23 Biomarcador para monitorear pacientes.

Country Status (21)

Country Link
US (1) US20120028279A1 (es)
EP (1) EP2411815B1 (es)
JP (1) JP5774578B2 (es)
KR (1) KR20110138354A (es)
CN (1) CN102362184B (es)
AU (1) AU2010227611B2 (es)
BR (1) BRPI1009892A2 (es)
CA (1) CA2756133A1 (es)
CO (1) CO6450670A2 (es)
DK (1) DK2411815T3 (es)
ES (1) ES2555858T3 (es)
HK (1) HK1161644A1 (es)
HU (1) HUE026194T2 (es)
IL (1) IL214611A (es)
MX (1) MX2011010061A (es)
NZ (1) NZ595290A (es)
RU (1) RU2542435C2 (es)
SG (2) SG174507A1 (es)
TW (1) TWI470225B (es)
WO (1) WO2010108908A1 (es)
ZA (1) ZA201106890B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596325A (en) 2009-07-10 2013-11-29 Transgene Sa Biomarker for selecting patients and related methods
WO2013177470A1 (en) * 2012-05-23 2013-11-28 Genentech, Inc. Selection method for therapeutic agents

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6054438A (en) 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
EP2112225A1 (en) 1996-07-25 2009-10-28 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
EP0958526B1 (en) * 1997-02-06 2005-06-15 University College Dublin Electrochromic system
AU727308B2 (en) * 1997-02-24 2000-12-07 Dana-Farber Cancer Institute Recombinant pox virus for immunization against muc1 tumor-associated antigen
CN1248919A (zh) * 1997-03-07 2000-03-29 林昭 以细菌菌体成分为有效成分的癌症免疫治疗剂
JPH10306029A (ja) * 1997-03-07 1998-11-17 Akira Hayashi 細菌の菌体成分を有効成分とする癌免疫療法剤
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9819726D0 (en) 1998-09-11 1998-11-04 Advanced Environmental Enginee Vapour recovery system
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
AU761567B2 (en) 1999-02-04 2003-06-05 Geron Corporation Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer
WO2000050573A1 (fr) 1999-02-22 2000-08-31 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
CN1382218A (zh) 1999-11-15 2002-11-27 昂尼克斯药物公司 溶瘤腺病毒
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
KR100830295B1 (ko) 2000-11-23 2008-05-16 버베리안 노딕 에이/에스 변형된 백시니아 앙카라 바이러스 변형체
CA2441809C (en) * 2001-03-27 2014-07-22 Biomira, Inc. Liposomal vaccines comprising dilipopeptides for modulating t1 and t2 immune responses
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
DK1509244T3 (da) * 2002-06-06 2011-10-24 Immunicum Ab Ny fremgangsmåde og præparat til at producere en cellulær allogen vaccine
US7998492B2 (en) 2002-10-29 2011-08-16 Coley Pharmaceutical Group, Inc. Methods and products related to treatment and prevention of hepatitis C virus infection
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
FR2855758B1 (fr) 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
KR20060123138A (ko) * 2003-10-10 2006-12-01 파우더젝트 백신, 인코포레이티드 방법
FR2862648B1 (fr) 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
JPWO2005067981A1 (ja) * 2004-01-13 2007-12-27 株式会社ディナベック研究所 免疫刺激性サイトカインをコードするマイナス鎖ｒｎａウイルスベクターを用いる腫瘍の遺伝子治療
WO2005118884A1 (en) * 2004-05-28 2005-12-15 The United States Of America As Represented By The Secretary Of The Navy A method for the rapid diagnosis of infectious disease by detection and quantitation of microorganism induced cytokines
CN101035901A (zh) * 2004-07-22 2007-09-12 细胞基因系统有限公司 腺病毒载体中转基因的插入
JP5024830B2 (ja) * 2004-10-25 2012-09-12 ステーテンズ セーラム インスティテュート クラミジア・トラコマチス（Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓ）抗原のワクチンおよび診断への使用
WO2006116423A2 (en) * 2005-04-26 2006-11-02 Eisai Co., Ltd Compositions and methods for cancer immunotherapy
PT2366400E (pt) * 2005-06-28 2016-02-02 Oncothyreon Inc Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1)
US20090305258A1 (en) * 2006-02-17 2009-12-10 Paolo La Colla Methods for the diagnosis of proliferative and/or conformational diseases
JP5382529B2 (ja) * 2007-09-10 2014-01-08 独立行政法人理化学研究所 ヒト樹状細胞の評価方法およびヒト細胞免疫療法剤

Also Published As

Publication number Publication date
HK1161644A1 (en) 2012-07-27
SG174507A1 (en) 2011-10-28
HUE026194T2 (en) 2016-05-30
TWI470225B (zh) 2015-01-21
AU2010227611B2 (en) 2014-05-29
TW201038943A (en) 2010-11-01
KR20110138354A (ko) 2011-12-27
EP2411815A1 (en) 2012-02-01
ZA201106890B (en) 2012-06-27
IL214611A0 (en) 2011-09-27
CO6450670A2 (es) 2012-05-31
JP5774578B2 (ja) 2015-09-09
CN102362184B (zh) 2015-04-08
EP2411815B1 (en) 2015-11-11
CN102362184A (zh) 2012-02-22
JP2012521549A (ja) 2012-09-13
CA2756133A1 (en) 2010-09-30
RU2011142612A (ru) 2013-04-27
DK2411815T3 (en) 2015-11-30
ES2555858T3 (es) 2016-01-11
WO2010108908A1 (en) 2010-09-30
NZ595290A (en) 2012-09-28
AU2010227611A1 (en) 2011-08-25
BRPI1009892A2 (pt) 2016-03-15
IL214611A (en) 2015-07-30
US20120028279A1 (en) 2012-02-02
RU2542435C2 (ru) 2015-02-20
SG2014014021A (en) 2014-07-30

Similar Documents

Publication Publication Date Title
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
MX358517B (es) Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon.
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
MX2013000674A (es) Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
EA201490230A1 (ru) Применение меченых ингибиторов hsp90
MX2015007714A (es) Agente terapeutico de direccionamiento a glipicano 3 (gpc3) que es administrado a pacientes para quienes la terapia con agentes terapeuticos de direccionamiento a gpc3 es eficaz.
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
MX2010005244A (es) Composiciones y métodos para la terapia y el diagnóstico de influenza.
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
MX2012001716A (es) Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
EP2560681A4 (en) USE OF TAU FOR MONITORING IMMUNOTHERAPY
TR201904638T4 (tr) pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi.
NZ701607A (en) Therapeutic use of chardonnay seed products
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
IN2012DN06309A (es)
TR201907241T4 (tr) IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2.
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
BR112012026224A2 (pt) métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia
MX2011010920A (es) Biomarcador para monitorear pacientes.
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
WO2014040891A3 (de) Verfahren zur diagnose eines molekularen phänotyps eines an einer mit chronischen entzündungen einhergehenden erkrankung leidenden patienten
MX2011010061A (es) Biomarcador para monitorear pacientes.
EA201490201A1 (ru) Выявление экспрессии гена prame при раковом заболевании
BR112013025197A2 (pt) métodos para tratar doença de alzheimer e para avaliar a eficáca de uma terapia destinada a tratar doença de alzheimer
ES2481517A2 (es) Método para el diagnóstico de la enfermedad de parkinson en estadios tempranos

Legal Events

Date Code Title Description
FG Grant or registration